Publication:
Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma

dc.contributor.authorErtaş, Hülya
dc.contributor.authorOcak, Birol
dc.contributor.buuauthorCANER, BURCU
dc.contributor.buuauthorÇubukçu, Erdem
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
dc.contributor.orcid0000-0002-5872-8825
dc.contributor.researcheridHJH-6371-2023
dc.date.accessioned2024-11-08T12:45:45Z
dc.date.available2024-11-08T12:45:45Z
dc.date.issued2022-02-21
dc.description.abstractIntroduction Hyperprogression is a specific type of response seen with immunotherapy that is observed in all malignancies with a frequency of 9% - 29%, characterized by a rapid increase in tumor burden. Many possible related factors and possible markers have been evaluated but a clinical or laboratory parameter associated with hyperprogression has not yet been established. For renal cell carcinoma, hypercalcemia is known to be a poor prognostic factor but it has not been linked to hyperprogression. Case report We retrospectively evaluated 52 patients diagnosed with renal cell carcinoma who had nivolumab treatment in any line. 3 of 9 patients who had hyperprogression were noticed to have hypercalcemia preceding hyperprogression. Here we present those 3 cases who developed hypercalcemia after nivolumab and had hyperprogression at follow-up. Management and outcome All cases had less than 4 courses of nivolumab and showed hyperprogression in assessment. Nivolumab was discontinued. However, patients' survival was extremely poor, as expected. Discussion The development of hypercalcemia may help predict hyperprogression in patients with renal cell carcinoma who receive immunotherapy. In such cases, early evaluation of progression and cessation of nivolumab may be considered.
dc.identifier.doi10.1177/10781552221077418
dc.identifier.endpage1649
dc.identifier.issn1078-1552
dc.identifier.issue7
dc.identifier.startpage1645
dc.identifier.urihttps://doi.org/10.1177/10781552221077418
dc.identifier.urihttps://hdl.handle.net/11452/47652
dc.identifier.volume28
dc.identifier.wos000762224900001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.journalJournal Of Oncology Pharmacy Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTherapy
dc.subjectRenal cell carcinoma
dc.subjectHyperprogression
dc.subjectNivolumab
dc.subjectHypercalcemia
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOncology
dc.subjectPharmacology & pharmacy
dc.titleHyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication9807c94e-65ab-4632-b31b-dc9b1db15d7d
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublication.latestForDiscovery9807c94e-65ab-4632-b31b-dc9b1db15d7d

Files

Collections